2. Autophagy
  3. Autophagy
  4. TFEB activator 1

TFEB activator 1 is an orally effective, mTOR-independent activator of TFEB. TFEB activator 1 significantly promotes the nuclear translocation of Flag-TFEB with an EC50 of 2167 nM. TFEB activator 1 enhances autophagy without inhibiting the mTOR pathway and has the potential for neurodegenerative diseases treatment.

For research use only. We do not sell to patients.

TFEB activator 1 Chemical Structure

TFEB activator 1 Chemical Structure

CAS No. : 39777-61-2

Size Price Stock Quantity
Free Sample (0.1 - 0.5 mg)   Apply Now  
5 mg USD 72 In-stock
10 mg USD 110 In-stock
25 mg USD 220 In-stock
50 mg USD 385 In-stock
100 mg USD 605 In-stock
200 mg   Get quote  
500 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 4 publication(s) in Google Scholar

TFEB activator 1 Related Antibodies

Top Publications Citing Use of Products

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

TFEB activator 1 is an orally effective, mTOR-independent activator of TFEB. TFEB activator 1 significantly promotes the nuclear translocation of Flag-TFEB with an EC50 of 2167 nM. TFEB activator 1 enhances autophagy without inhibiting the mTOR pathway and has the potential for neurodegenerative diseases treatment[1].

IC50 & Target

EC50: 2167 nM (Flag-TFEB nuclear translocation)[1]
Cellular Effect
Cell Line Type Value Description References
HCT-116 GI50
4 μM
Compound: GO-Y019
Growth inhibition of human HCT116 cells after 48 hrs by MTS assay
Growth inhibition of human HCT116 cells after 48 hrs by MTS assay
[PMID: 20060305]
HeLa IC50
161 μM
Compound: B6
Cytotoxicity against human HeLa cells after 72 hrs by MTT assay
Cytotoxicity against human HeLa cells after 72 hrs by MTT assay
[PMID: 19243951]
HL-60 IC50
< 12.6 μM
Compound: B6
Cytotoxicity against human HL60 cells after 72 hrs by MTT assay
Cytotoxicity against human HL60 cells after 72 hrs by MTT assay
[PMID: 19243951]
KB IC50
< 12.6 μM
Compound: B6
Cytotoxicity against human KB cells after 72 hrs by MTT assay
Cytotoxicity against human KB cells after 72 hrs by MTT assay
[PMID: 19243951]
MDA-MB-231 GI50
1 μM
Compound: 29; GO-Y019
Growth inhibition of human MDA-MB-231 cells measured after 72 hrs by microplate reader analysis
Growth inhibition of human MDA-MB-231 cells measured after 72 hrs by microplate reader analysis
[PMID: 32172081]
RPMI-7951 GI50
2.3 μM
Compound: 29; GO-Y019
Growth inhibition of human RPMI-7951 cells measured after 72 hrs by microplate reader analysis
Growth inhibition of human RPMI-7951 cells measured after 72 hrs by microplate reader analysis
[PMID: 32172081]
In Vitro

TFEB activator 1 (Compound C1) activates TFEB (transcription factor EB) by directly binding to TFEB and promotes its entry into the nucleus, without affecting TFEB phosphorylation or inhibiting the activities of MTOR and MAPK1/ERK2-MAPK3/ERK1[1].
? TFEB activator 1 (1 μM; for 12 h) significantly increases the levels of LC3B-II, the lipidated and phagophore- or autophagosome-associated form of MAP1LC3B/LC3B (microtubule-associated protein 1 light chain 3 β) in N2a cells[1].
? TFEB activator 1 (0.2-1 μM) dose-dependently increases the levels of LC3-II and SQSTM1/p62 (sequestosome 1) in N2a cells[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

TFEB activator 1 Related Antibodies

Western Blot Analysis[1]

Cell Line: N2a cells
Concentration: 0, 0.2, 0.4, 0.6, 0.8 and 1 μM
Incubation Time: 12 hours
Result: Treatment dose-dependently increased the levels of LC3-II and SQSTM1/p62 (sequestosome 1).
In Vivo

The medium lethal dose (LD50) value of TFEB activator 1 (Compound C1) is 175 mg/kg in the acute toxicity assay (single-dose i.v. tail vein injection; in rats) [1].
? Short-term oral administration of TFEB activator 1 (low dosage 10 mg/kg and high dosage 25 mg/kg; for 24 h) dose-dependently increases the expression of LC3B-II and TFEB in the liver, frontal cortex and striatum of the brain[1].
? Chronic administration of TFEB activator 1 (10 mg/kg per day; orally administered by gavage) activates TFEB and enhances autophagy in rat brains[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Adult male Sprague-Dawley (SD) rats weighing 350 to 400 g[1]
Dosage: 10 mg/kg and 25 mg/kg
Administration: Short-term oral administration; for 24 hours
Result: Activated TFEB and enhanced autophagy and lysosome biogenesis in rat brain.
Animal Model: Adult male Sprague-Dawley (SD) rats weighing 350 to 400 g[1]
Dosage: 10 mg/kg
Administration: Chronic oral administration; daily; for 21 days
Result: Activated TFEB and enhanced autophagy in rat brains.
Molecular Weight

294.34

Formula

C19H18O3
CAS No.
Appearance

Solid

Color

Light yellow to yellow

SMILES

O=C(/C=C/C1=CC=CC=C1OC)/C=C/C2=CC=CC=C2OC
Shipping

Room temperature in continental US; may vary elsewhere.
Storage
Powder -20°C 3 years
4°C 2 years

*The compound is unstable in solutions, freshly prepared is recommended.

Solvent & Solubility
In Vitro: 

DMSO : 125 mg/mL (424.68 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 3.3974 mL 16.9872 mL 33.9743 mL
5 mM 0.6795 mL 3.3974 mL 6.7949 mL
View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. The compound is unstable in solutions, freshly prepared is recommended.

  • Molarity Calculator

  • Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass
=
Concentration
×
Volume
×
Molecular Weight *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start)

C1

×
Volume (start)

V1

=
Concentration (final)

C2

×
Volume (final)

V2

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

  • Protocol 1

    Add each solvent one by one:  10% DMSO    90% Corn Oil

    Solubility: ≥ 6.25 mg/mL (21.23 mM); Clear solution

    This protocol yields a clear solution of ≥ 6.25 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (62.5 mg/mL) to 900 μL Corn oil, and mix evenly.

For the following dissolution methods, please prepare the working solution directly. It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

  • Protocol 1

    Add each solvent one by one:  50% PEG300    50% Saline

    Solubility: 4 mg/mL (13.59 mM); Suspended solution; Need ultrasonic

In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

g

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
%
DMSO +
% 
+
%
Tween-80 +
%
Saline
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Calculation results:
Working solution concentration: mg/mL
Method for preparing stock solution: mg drug dissolved in μL  DMSO (Stock solution concentration: mg/mL).

*The compound is unstable in solutions, freshly prepared is recommended.

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.
 If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
References

Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. The compound is unstable in solutions, freshly prepared is recommended.

Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
DMSO 1 mM 3.3974 mL 16.9872 mL 33.9743 mL 84.9358 mL
5 mM 0.6795 mL 3.3974 mL 6.7949 mL 16.9872 mL
10 mM 0.3397 mL 1.6987 mL 3.3974 mL 8.4936 mL
15 mM 0.2265 mL 1.1325 mL 2.2650 mL 5.6624 mL
20 mM 0.1699 mL 0.8494 mL 1.6987 mL 4.2468 mL
25 mM 0.1359 mL 0.6795 mL 1.3590 mL 3.3974 mL
30 mM 0.1132 mL 0.5662 mL 1.1325 mL 2.8312 mL
40 mM 0.0849 mL 0.4247 mL 0.8494 mL 2.1234 mL
50 mM 0.0679 mL 0.3397 mL 0.6795 mL 1.6987 mL
60 mM 0.0566 mL 0.2831 mL 0.5662 mL 1.4156 mL
80 mM 0.0425 mL 0.2123 mL 0.4247 mL 1.0617 mL
100 mM 0.0340 mL 0.1699 mL 0.3397 mL 0.8494 mL
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

TFEB activator 1 Related Classifications

Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

TFEB activator 139777-61-2TFEB activator1TFEB activator-1AutophagyorallyeffectivemTOR-independentTFEBneurodegenerativediseaseInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Salutation

Applicant Name *

 

Email Address *

Phone Number *

 

Organization Name *

Department *

 

Requested quantity *

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
TFEB activator 1
Cat. No.:
HY-135825
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

English - EN (393 KB) Français - FR (393 KB) Deutsch - DE (393 KB) Norwegian - NO (393 KB) Español - ES (393 KB) Swedish - SV (393 KB)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.